The COVID-19 global pandemic has led to more than 470,000 deaths. This disease is especially perilous for the elderly - 80% of deaths in the US have been individuals over the age of 65, and the social isolation created by lockdowns have increased risks of serious physical and mental health issues. COVID-19 is a heterogeneous disease exhibiting a broad spectrum of symptoms, ranging from mild (e.g. loss of smell, dry cough) to critical (e.g. cytokine storm, renal failure, cardiovascular damage, respiratory failure, lethal blood clotting, neurological disorders). This clinical heterogeneity demands a precision medicine approach that elucidates distinct pathways underlying the disease, develops treatments for each pathway, and defines biomarker patterns to diagnose patients for classification within the subsets. A key benefit of precision medicine is that drugs may be repurposed or may already exist to treat specific subsets of infected individuals. For example, one critical outcome for COVID-19 infection is the onset of a cytokine storm, in which the body's immune system gets caught in a positive feedback loop, leading to shock and rapid failure of multiple organs. There are existing drugs for treating cytokine storm syndrome, but practitioners have no clear guidelines if such treatments are beneficial or destructive. If the individual is not in a hyperinflammatory state, the administration of these drugs could cripple their immune response, leading to increased viral load. Plasma biomarker patterns of proteins and metabolites hold potential to identify impending cytokine storms and other lethal outcomes. To advance precision medicine for COVID-19 treatment, this work will generate large-scale omics data and evaluate levels of proteins and metabolites for plasma drawn from 350 COVID-19 positive cases and 750 normal controls. These data will be immediately released to the research community. Our research team will take a concerted multipronged approach for analyzing these data using diverse complementary techniques. Our labs' research focuses on the discovery of combinations of genes and proteins expressing synchronously and the associations of these combinations with traits of interest, as well as endophenotype discovery. In addition to thorough single analyte analyses, this research will employ three computational strategies to reveal combinations of factors defining patterns: 1) network modeling, 2) explainable-AI systems biology, and 3) linear programming. These intensive analyses will require significant computational resources and we will utilize Summit at Oak Ridge National Laboratory, one of the most powerful supercomputers in the world, for these tasks. The comprehensive protein and metabolite profiles, based on a large cohort of COVID-19 cases and normal controls, along with our rigorous interrogation of these data for complex biomarker patterns indicative of patient outcomes, hold unprecedented potential to drive solid advances in precision medicine and to reduce mortality rates due to COVID-19. In addition, this research will provide an agile model for use when tackling other heterogeneous diseases plaguing humankind, as well as novel viruses that may arise in the future.
The COVID-19 pandemic is exceptionally detrimental for the elderly, as they comprise 80% of deaths in the US and are at elevated risks for serious physical and mental health issues due to social isolation. COVID-19 is a heterogeneous disease that exhibits a range of diverse symptoms, demanding a precision medicine approach in which treatments for each distinct outcome are developed, biomarker patterns to diagnose patients for classification into an outcome group are defined, and new candidate drug targets are generated for each outcome. In order to lay the foundation for a precision medicine approach for treating COVID-19, this work will generate a highly-phenotyped large-scale omics dataset including blood proteomics and metabolomics from 350 COVID-19 positive cases and 750 uninfected healthy individuals and will intensely analyze these data using diverse complementary high-performance computing techniques, including network modeling with enhanced accuracy, explainable-AI systems biology incorporating diverse data, and pioneering linear programming producing optimal associations, thereby illuminating complex proteomic and metabolomic biomarker patterns associated with each critical disease outcome and generating novel candidate drug targets.
|Cruchaga, Carlos; Del-Aguila, Jorge L; Saef, Benjamin et al. (2018) Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. Alzheimers Dement 14:205-214|
|Deming, Yuetiva; Li, Zeran; Benitez, Bruno A et al. (2018) Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease? Expert Opin Ther Targets 22:587-598|
|Maxwell, Taylor J; Corcoran, Chris; Del-Aguila, Jorge L et al. (2018) Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels. Alzheimers Res Ther 10:86|
|Yan, Qi; Nho, Kwangsik; Del-Aguila, Jorge L et al. (2018) Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Mol Psychiatry :|
|Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872|
|Li, Zeran; Del-Aguila, Jorge L; Dube, Umber et al. (2018) Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. Genome Med 10:43|
|Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558|
|Del-Aguila, Jorge L; Fernández, Maria Victoria; Schindler, Suzanne et al. (2018) Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline. J Alzheimers Dis 62:745-756|
|Fernández, Maria Victoria; Kim, Jong Hun; Budde, John P et al. (2017) Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease. PLoS Genet 13:e1007045|
|Ibanez, Laura; Dube, Umber; Saef, Benjamin et al. (2017) Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. BMC Neurol 17:198|
Showing the most recent 10 out of 19 publications